Busulfan

證據等級: L5

預測適應症: 10 個

Busulfan: Repurposing Evaluation — Pending Predicted Indication

One-Sentence Summary

Busulfan is a bifunctional alkylating agent historically established for chronic myelogenous leukemia (CML) and pre-transplant conditioning regimens prior to hematopoietic stem cell transplantation (HSCT). The current evidence pack contains no TxGNN-predicted new indications, and critical data including mechanism of action and safety information remain unresolved. This report documents the current data status and defines the remediation steps required before repurposing evaluation can proceed.

Quick Overview

Item	Content
Original Indication	Chronic myelogenous leukemia / pre-transplant conditioning (based on established pharmacological knowledge; Taiwan package insert not retrieved)
Predicted New Indication	None generated in current evidence pack
TxGNN Prediction Score	Not available
Evidence Level	Cannot be determined
Taiwan Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Since the TxGNN pipeline returned no predicted indications in this evidence pack, a formal mechanistic bridge analysis cannot be performed at this stage.

From established pharmacological knowledge, busulfan is a bifunctional alkylating agent that cross-links DNA strands, disrupting replication in rapidly dividing cells. This mechanism underlies its long-standing use in CML (myelosuppression as therapeutic intent) and its role as a myeloablative conditioning agent before HSCT to eliminate residual haematopoietic cells prior to donor engraftment.

To evaluate whether this mechanism is applicable to any new indication, TxGNN predictions must first be generated and reviewed. Once candidate disease associations are available, mechanistic plausibility can be assessed in the context of shared biological pathways.

Cytotoxicity

Busulfan is an antineoplastic alkylating agent; cytotoxicity assessment applies.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Alkylating agent (bifunctional alkyl sulphonate)
Myelosuppression Risk	High — severe, prolonged myelosuppression is the primary dose-limiting toxicity; nadir typically at 11–30 days
Emetogenicity Classification	Moderate (standard-dose oral regimen); High (high-dose IV conditioning)
Monitoring Items	CBC with differential (daily during conditioning), liver function tests, renal function, busulfan plasma levels (therapeutic drug monitoring for IV conditioning), serum electrolytes
Handling Protection	Must follow cytotoxic drug handling regulations; IV formulation requires dedicated closed-system drug transfer device

Safety Considerations

Please refer to the package insert for safety information.

Note: Taiwan package insert retrieval returned a positive result in the query log (query ID 4, status: success), but the parsed content was not included in this evidence pack. Warnings and contraindications should be extracted from that source as the next remediation step.

Conclusion and Next Steps

Decision: Hold

Rationale: The evidence pack is missing TxGNN predictions entirely, and both MOA and safety data remain unresolved — making it impossible to evaluate any repurposing hypothesis or perform a safety pre-screen at this stage.

To proceed, the following is needed:

Re-run TxGNN prediction pipeline — generate candidate disease associations for Busulfan (DB01008) so that a repurposing hypothesis can be identified
Extract Taiwan package insert content — the query log confirms a successful retrieval (query ID 4); parse warnings, contraindications, and dosage information from the retrieved document
Query DrugBank API for full MOA data — populate mechanism of action to enable target-pathway analysis
Retrieve DDI data — query drug interaction databases (DDI query returned not_found; broaden search scope or use alternative sources)
Re-submit evidence pack — once the above four items are resolved, re-generate the evidence pack and proceed to full repurposing evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.